Hope S. Rugo, MD, FASCO

This concluding segment addresses cumulative toxicities affecting long-term antibody-drug conjugate tolerability, with Hope Rugo, MD and Aaron Lisberg, MD discussing edema, fatigue, and strategies for sustained therapy in breast and lung cancer.

Hope Rugo, MD; Liz Castronovo, NP; and Stephanie McDonald, NP, discuss practical approaches to thrombocytopenia management during antibody-drug conjugate (ADC) therapy, emphasizing that platelet thresholds should be individualized rather than applied as rigid cutoffs.

Hope Rugo, MD; Aaron Lisberg, MD; and Liz Castronovo, NP, discuss hematologic toxicity management during antibody-drug conjugate (ADC) therapy across breast and lung cancer, with particular attention to neutropenia, febrile neutropenia, and growth factor strategies.

This segment focuses on diarrhea management with antibody-drug conjugates (ADCs) across breast and lung cancer, particularly sacituzumab govitecan (SG) and its irinotecan-like toxicity profile due to the SN-38 payload.

Dr. Rugo, NP Stephanie McDonald, and NP Liz Castronovo discussed the distinct gastrointestinal challenges posed by antibody-drug conjugates (ADCs) such as trastuzumab deruxtecan and datopotamab deruxtecan, focusing on "long-delayed nausea" that can persist for days to a week after infusion, a pattern that sets these agents apart from conventional chemotherapy-induced nausea.

The experts conclude their discussion on ocular toxicity by exploring emerging research aimed at addressing the underlying mechanisms of ADC-associated corneal changes.

The experts continue their discussion on ocular toxicity, addressing the practical challenges of distinguishing antibody-drug conjugate (ADC)-related changes from baseline dry eye disease and establishing effective referral pathways.

In this expert discussion, Hope Rugo, MD; Neel Pasricha, MD; and Sarah Sunshine, MD explore ocular adverse events associated with antibody-drug conjugates (ADCs), examining pathophysiology, prevention, and multidisciplinary management.

In this expert discussion, Dr. Hope Rugo, Dr. Aaron Lisberg, Liz Castronovo, NP, and Stephanie McDonald, NP examine mucositis and stomatitis management in antibody-drug conjugate (ADC) therapy for breast and lung cancer.

This discussion brings together Dr. Hope Rugo, Dr. Aaron Lisberg, and Stephanie McDonald, NP discuss interstitial-lung-disease (ILD) risk assessment and monitoring strategies for patients receiving antibody-drug conjugates (ADCs) following radiation therapy.

Panelists discuss proactive ILD risk assessment, vigilant monitoring, and multidisciplinary management to balance safety and efficacy of ADC therapies in breast and lung cancer.

Panelists discuss proactive ILD surveillance, patient education, and early intervention strategies to support safe and effective ADC therapy while minimizing pulmonary risks.

Panelists discuss proactive ILD risk assessment, vigilant monitoring, and multidisciplinary management to balance safety and efficacy of ADC therapies in breast and lung cancer.

Rapid readout: oral SERD elacestrant plus everolimus or abemaciclib boosts PFS in ER+/HER2- metastatic breast cancer with manageable safety.

Experts discuss the future of breast cancer treatment, emphasizing personalized approaches and the potential of new oral therapies to improve outcomes.

Experts discuss the implications of the SERENA-6 trial, highlighting the potential benefits of early oral SERD deployment in breast cancer treatment.

Researchers analyze real-world data on ESR1-mutated breast cancer treatments, revealing promising outcomes and insights for patient care strategies.

Explore the impact of elacestrant on ESR1-mutated breast cancer, revealing real-world data insights and genomic factors influencing treatment outcomes.

Experts discuss the integration of oral SERDs like elacestrant into clinical practice, highlighting their benefits for ESR1 mutant populations in breast cancer treatment.

Hope S. Rugo, MD, and Seth Wander, MD, PhD, discuss treatment selection after CDK4/6 inhibitor progression in advanced ER-positive breast cancer.

Hope S. Rugo, MD, highlights emerging research with targeted therapies and oral SERDs that may influence the HR-positive breast cancer treatment paradigm.

Hope S. Rugo, MD, discusses an open-label umbrella study evaluating elacestrant in combination with everolimus or abemaciclib in ER-positive/HER2-negative advanced breast cancer.

Presented by Dr. Hope S. Rugo, this slide deck presents updated phase 1b/2 safety and efficacy results from the ELEVATE trial of elacestrant combinations with ribociclib and everolimus in ER+/HER2- metastatic breast cancer, highlighting their clinical activity and potential as an endocrine therapy backbone.

Hope S. Rugo, MD, discusses the safety profile of alpelisib for the treatment of PI3K-mutant HR-positive/HER2-negative advanced breast cancer.

Hope S. Rugo, MD, discusses quality of life data from the phase 3 SERENA-6 study.

Hope Rugo, MD, discusses the application of findings from the DESTINY-Breast09 trial of T-DXd plus pertuzumab in HER2-positive breast cancer.

Hope Rugo, MD, discusses the evolving use of antibody-drug conjugates in HER2-positive breast cancer.

Hope S. Rugo, MD, FASCO, discusses updated safety findings from the ELEVATE trial of elacestrant-based combinations in ER+/HER2– metastatic breast cancer.

Hope S. Rugo, MD discusses managing treatment-related toxicities within the scope of the current breast cancer treatment paradigm.

Drs Graff, Mahtani, McCann, and Rugo share moments that sparked their interest in oncology and setbacks they overcame when building their careers.